Genmab — Februar 2016
-
Morgenkommentar fra Danske Equities: We believe the recent share price decline is unwarranted and see a buying opportunity ahead of the near-term interim readout of the Darzalex Phase 3 trials in relapsed multiple myeloma. We keep our Buy but lower the 12M target price to DKK1,025 (DKK1,110) after SOTP adjustments related to FX, Arzerra in oncology and Darzalex in smoldering myeloma.
-
haha - danske bruger kursfaldet som lejlighed til at fidle ved dcf'en. Mon der er andre analytikere, der heller ikke mener deres analyser seriøst?
-
Det undrer mig dingle.
-
hvilket, helge?
-
At Danske "fidler".
-
De har vel fået lidt højdeskræk og kravler lidt ned af tårnet nu. Vi skal vel ikke tage det mere end en reminder om at analytiker targets skal tages med meget store gran salt
-
Jeps Dingle.
-
Det ser ud til at vi endelig får lidt rebound
-
fredag var sgu en sørgelig oplevelse
-
Det er et udsalg, der er til at føle på. Mon der stadig er antipati imod biotek som aktivklasse?
-
...eller er det bare GEN, udlandet ikke kan lide...
-
he new therapy's potential lies in its unique mechanism of action. Darzalex is a first-in-class antibody that initiates an immune response after binding to CD38, a protein found on the surface of multiple myeloma cells. This approach has led to impressive response rates in heavily pre-treated patients. Although not measured head to head, it also appears far more tolerable than its contenders.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind